Baijin Life Science (HKG:1466) said it expects to record up to HK$43 million in loss for the fiscal year ended March 31, widening from a loss of HK$100,000 a year earlier, according to a Monday filing with the Hong Kong bourse.
The firm attributed the higher loss to a drop in revenue and gross profit, mainly from its jewellery business.
The company also saw a rise in the cost of sales from its skincare business.
The company's financial results are due June 30.